Back to: products

Global Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing

PrintEmail
Nov 2021 - 180 Pages - From $3,200
(Excel Data Sheet: $2,000)
Description

The report cover may be different from the image shown.

Product and Price

By clicking the Add to Shopping Cart button, you certify to agree with our Terms of Service.

Global biosimilars market will reach $113.25 billion by 2030, growing by 25.7% annually over 2020-2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.
Highlighted with 89 tables and 90 figures, this 180-page report “Global Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Region.

Based on Product Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Recombinant Non-glycosylated Biosimilars
o Insulin
o Recombinant Human Growth Hormone (rHGH)
o Granulocyte Colony Stimulating Factor
o Interferon
• Recombinant Glycosylated Biosimilars
o Monoclonal Antibodies (mAb)
o Erythropoietin (EPO)
o Follicle Stimulating Hormone
• Recombinant Peptides and Others
o Tumor Necrosis Factor (TNF)-Inhibitor
o Parathyroid Hormone
o Enzymes, Immunomodulators, GnRH Analogs and Others

Based on Indication, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Cancer
• Autoimmune Disease
• Blood Disorder
• Diabetes
• Growth Hormone Deficiency
• Infectious Diseases
• Other Indications

Based on Manufacturing, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Contract Manufacturing
• Inhouse Manufacturing

Based on End User, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Hospitals and Clinics
• Research Institutes
• Other End Users

Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (Turkey, Iran, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Product Type, Indication, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
AMEGA Biotech S.A.
Apotex Inc.
Biocon Ltd
Biogen Inc.
Boehringer Ingelheim
Celltrion, Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
Intas Pharmaceuticals Ltd.
LG Chem, Ltd.
Merck and Co. Inc.
Mylan N.V.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Sandoz International GmbH
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 23
2.1.2 Impact of COVID-19 on the Market 26
2.2 Major Growth Drivers 28
2.3 Market Restraints and Challenges 33
2.4 Emerging Opportunities and Market Trends 36
2.5 Porter’s Fiver Forces Analysis 40
3 Segmentation of Global Market by Product Type 44
3.1 Market Overview by Product Type 44
3.2 Recombinant Non-glycosylated Biosimilars 46
3.2.1 Insulin 48
3.2.2 Recombinant Human Growth Hormone (rHGH) 49
3.2.3 Granulocyte Colony Stimulating Factor 50
3.2.4 Interferon 51
3.3 Recombinant Glycosylated Biosimilars 52
3.3.1 Monoclonal Antibodies (mAb) 53
3.3.2 Erythropoietin (EPO) 54
3.3.3 Follicle Stimulating Hormone 55
3.4 Recombinant Peptides and Others 56
3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 57
3.4.2 Parathyroid Hormone 58
3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 59
4 Segmentation of Global Market by Indication 60
4.1 Market Overview by Indication 60
4.2 Cancer 62
4.3 Autoimmune Disease 63
4.4 Blood Disorder 64
4.5 Diabetes 65
4.6 Growth Hormone Deficiency 66
4.7 Infectious Diseases 67
4.8 Other Indications 68
5 Segmentation of Global Market by Manufacturing 69
5.1 Market Overview by Manufacturing 69
5.2 Contract Manufacturing 71
5.3 Inhouse Manufacturing 72
6 Segmentation of Global Market by End User 73
6.1 Market Overview by End User 73
6.2 Hospitals and Clinics 75
6.3 Research Institutes 76
6.4 Other End Users 77
7 Segmentation of Global Market by Region 78
7.1 Geographic Market Overview 2019-2030 78
7.2 North America Market 2019-2030 by Country 82
7.2.1 Overview of North America Market 82
7.2.2 U.S. 86
7.2.3 Canada 96
7.2.4 Mexico 98
7.3 European Market 2019-2030 by Country 100
7.3.1 Overview of European Market 100
7.3.2 Germany 106
7.3.3 U.K. 108
7.3.4 France 110
7.3.5 Spain 112
7.3.6 Italy 114
7.3.7 Russia 116
7.3.8 Rest of European Market 118
7.4 Asia-Pacific Market 2019-2030 by Country 120
7.4.1 Overview of Asia-Pacific Market 120
7.4.2 Japan 124
7.4.3 China 127
7.4.4 Australia 129
7.4.5 India 131
7.4.6 South Korea 133
7.4.7 Rest of APAC Region 135
7.5 South America Market 2019-2030 by Country 137
7.5.1 Argentina 140
7.5.2 Brazil 142
7.5.3 Chile 144
7.5.4 Rest of South America Market 146
7.6 MEA Market 2019-2030 by Country 147
7.6.1 Turkey 150
7.6.2 Iran 152
7.6.3 South Africa 154
7.6.4 Other National Markets 156
8 Competitive Landscape 157
8.1 Overview of Key Vendors 157
8.2 New Product Launch, Partnership, Investment, and M&A 161
8.3 Company Profiles 162
AMEGA Biotech S.A. 162
Apotex Inc. 164
Biocon Ltd 165
Biogen Inc. 166
Boehringer Ingelheim 167
Celltrion, Inc. 168
Dr. Reddy’s Laboratories Ltd. 169
Eli Lilly and Company 170
Intas Pharmaceuticals Ltd. 171
LG Chem, Ltd. 172
Merck and Co. Inc. 173
Mylan N.V. 174
Pfizer Inc. 175
Samsung Biologics Co., Ltd. 176
Sandoz International GmbH 177
STADA Arzneimittel AG 178
Teva Pharmaceutical Industries Ltd. 179
RELATED REPORTS 180

List of Tables:

Table 1. Snapshot of Global Biosimilars Market in Balanced Perspective, 2019-2030 19
Table 2. Growth Rate of World GDP, 2020-2022 24
Table 3. World Health Spending by Region, $ bn, 2013-2020 32
Table 4. Main Product Trends and Market Opportunities in Global Biosimilars Market 36
Table 5. Global Biosimilars Market by Product Type, 2019-2030, $ mn 44
Table 6. Global Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, $ mn 47
Table 7. Global Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, $ mn 52
Table 8. Global Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, $ mn 56
Table 9. Global Biosimilars Market by Indication, 2019-2030, $ mn 60
Table 10. Global Biosimilars Market by Manufacturing, 2019-2030, $ mn 69
Table 11. Global Biosimilars Market by End User, 2019-2030, $ mn 73
Table 12. Global Biosimilars Market by Region, 2019-2030, $ mn 79
Table 13. Leading National Biosimilars Market, 2019 and 2030F, $ mn 81
Table 14. North America Biosimilars Market by Country, 2019-2030, $ mn 84
Table 15. U.S. Biosimilars Market by Product Type, 2019-2030, $ mn 89
Table 16. U.S. Biosimilars Market by Indication, 2019-2030, $ mn 89
Table 17. U.S. Biosimilars Market by End User, 2019-2030, $ mn 89
Table 18. FDA Approved Biosimilars in U.S., 2015-2020 90
Table 19. U.S. Select Pending Biosimilar BLAs as of December 2020 94
Table 20. U.S. Biosimilar Market Share (market share data through July 2020) 95
Table 21. Canada Biosimilars Market by Product Type, 2019-2030, $ mn 97
Table 22. Canada Biosimilars Market by Indication, 2019-2030, $ mn 97
Table 23. Canada Biosimilars Market by End User, 2019-2030, $ mn 97
Table 24. Mexico Biosimilars Market by Product Type, 2019-2030, $ mn 99
Table 25. Mexico Biosimilars Market by Indication, 2019-2030, $ mn 99
Table 26. Mexico Biosimilars Market by End User, 2019-2030, $ mn 99
Table 27. Europe Biosimilars Market by Country, 2019-2030, $ mn 103
Table 28. Approved Biosimilars in Europe 104
Table 29. Germany Biosimilars Market by Product Type, 2019-2030, $ mn 107
Table 30. Germany Biosimilars Market by Indication, 2019-2030, $ mn 107
Table 31. Germany Biosimilars Market by End User, 2019-2030, $ mn 107
Table 32. U.K. Biosimilars Market by Product Type, 2019-2030, $ mn 109
Table 33. U.K. Biosimilars Market by Indication, 2019-2030, $ mn 109
Table 34. U.K. Biosimilars Market by End User, 2019-2030, $ mn 109
Table 35. France Biosimilars Market by Product Type, 2019-2030, $ mn 111
Table 36. France Biosimilars Market by Indication, 2019-2030, $ mn 111
Table 37. France Biosimilars Market by End User, 2019-2030, $ mn 111
Table 38. Spain Biosimilars Market by Product Type, 2019-2030, $ mn 113
Table 39. Spain Biosimilars Market by Indication, 2019-2030, $ mn 113
Table 40. Spain Biosimilars Market by End User, 2019-2030, $ mn 113
Table 41. Italy Biosimilars Market by Product Type, 2019-2030, $ mn 115
Table 42. Italy Biosimilars Market by Indication, 2019-2030, $ mn 115
Table 43. Italy Biosimilars Market by End User, 2019-2030, $ mn 115
Table 44. Russia Biosimilars Market by Product Type, 2019-2030, $ mn 117
Table 45. Russia Biosimilars Market by Indication, 2019-2030, $ mn 117
Table 46. Russia Biosimilars Market by End User, 2019-2030, $ mn 117
Table 47. Biosimilars Market in Rest of Europe by Country, 2019-2030, $ mn 119
Table 48. APAC Biosimilars Market by Country, 2019-2030, $ mn 122
Table 49. Japan Biosimilars Market by Product Type, 2019-2030, $ mn 126
Table 50. Japan Biosimilars Market by Indication, 2019-2030, $ mn 126
Table 51. Japan Biosimilars Market by End User, 2019-2030, $ mn 126
Table 52. China Biosimilars Market by Product Type, 2019-2030, $ mn 128
Table 53. China Biosimilars Market by Indication, 2019-2030, $ mn 128
Table 54. China Biosimilars Market by End User, 2019-2030, $ mn 128
Table 55. Australia Biosimilars Market by Product Type, 2019-2030, $ mn 130
Table 56. Australia Biosimilars Market by Indication, 2019-2030, $ mn 130
Table 57. Australia Biosimilars Market by End User, 2019-2030, $ mn 130
Table 58. India Biosimilars Market by Product Type, 2019-2030, $ mn 132
Table 59. India Biosimilars Market by Indication, 2019-2030, $ mn 132
Table 60. India Biosimilars Market by End User, 2019-2030, $ mn 132
Table 61. South Korea Biosimilars Market by Product Type, 2019-2030, $ mn 134
Table 62. South Korea Biosimilars Market by Indication, 2019-2030, $ mn 134
Table 63. South Korea Biosimilars Market by End User, 2019-2030, $ mn 134
Table 64. Biosimilars Market in Rest of APAC by Country/Region, 2019-2030, $ mn 136
Table 65. South America Biosimilars Market by Country, 2019-2030, $ mn 139
Table 66. Argentina Biosimilars Market by Product Type, 2019-2030, $ mn 141
Table 67. Argentina Biosimilars Market by Indication, 2019-2030, $ mn 141
Table 68. Argentina Biosimilars Market by End User, 2019-2030, $ mn 141
Table 69. Brazil Biosimilars Market by Product Type, 2019-2030, $ mn 143
Table 70. Brazil Biosimilars Market by Indication, 2019-2030, $ mn 143
Table 71. Brazil Biosimilars Market by End User, 2019-2030, $ mn 143
Table 72. Chile Biosimilars Market by Product Type, 2019-2030, $ mn 145
Table 73. Chile Biosimilars Market by Indication, 2019-2030, $ mn 145
Table 74. Chile Biosimilars Market by End User, 2019-2030, $ mn 145
Table 75. MEA Biosimilars Market by Country, 2019-2030, $ mn 149
Table 76. Turkey Biosimilars Market by Product Type, 2019-2030, $ mn 151
Table 77. Turkey Biosimilars Market by Indication, 2019-2030, $ mn 151
Table 78. Turkey Biosimilars Market by End User, 2019-2030, $ mn 151
Table 79. Iran Biosimilars Market by Product Type, 2019-2030, $ mn 153
Table 80. Iran Biosimilars Market by Indication, 2019-2030, $ mn 153
Table 81. Iran Biosimilars Market by End User, 2019-2030, $ mn 153
Table 82. South Africa Biosimilars Market by Product Type, 2019-2030, $ mn 155
Table 83. South Africa Biosimilars Market by Indication, 2019-2030, $ mn 155
Table 84. South Africa Biosimilars Market by End User, 2019-2030, $ mn 155
Table 85. Breakdown of World Market by Key Vendor, 2020, % 159
Table 86. AMEGA Biotech S.A.: Company Snapshot 162
Table 87. AMEGA Biotech S.A.: Business Segmentation 162
Table 88. AMEGA Biotech S.A.: Product Portfolio 163
Table 89. AMEGA Biotech S.A.: Revenue, 2018-2020, $ mn 163

 

 

List of Figures:

Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 18
Figure 4. Global Biosimilars Market, 2019-2030, $ mn 20
Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019 21
Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 21
Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 22
Figure 8. Impact of COVID-19 on Business 26
Figure 9. Primary Drivers and Impact Factors of Global Biosimilars Market 28
Figure 10. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 31
Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 31
Figure 12. Primary Restraints and Impact Factors of Global Biosimilars Market 33
Figure 13. Investment Opportunity Analysis 37
Figure 14. Porter’s Fiver Forces Analysis of Global Biosimilars Market 40
Figure 15. Breakdown of Global Biosimilars Market by Product Type, 2019-2030, % of Revenue 45
Figure 16. Global Addressable Market Cap in 2021-2030 by Product Type, Value ($ mn) and Share (%) 45
Figure 17. Global Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, $ mn 46
Figure 18. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, $ mn 48
Figure 19. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, $ mn 49
Figure 20. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, $ mn 50
Figure 21. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, $ mn 51
Figure 22. Global Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, $ mn 52
Figure 23. Global Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, $ mn 53
Figure 24. Global Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, $ mn 54
Figure 25. Global Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, $ mn 55
Figure 26. Global Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, $ mn 56
Figure 27. Global Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, $ mn 57
Figure 28. Global Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, $ mn 58
Figure 29. Global Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, $ mn 59
Figure 30. Breakdown of Global Biosimilars Market by Indication, 2019-2030, % of Sales Revenue 61
Figure 31. Global Addressable Market Cap in 2021-2030 by Indication, Value ($ mn) and Share (%) 61
Figure 32. Global Biosimilars Market by Indication: Cancer, 2019-2030, $ mn 62
Figure 33. Global Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, $ mn 63
Figure 34. Global Biosimilars Market by Indication: Blood Disorder, 2019-2030, $ mn 64
Figure 35. Global Biosimilars Market by Indication: Diabetes, 2019-2030, $ mn 65
Figure 36. Global Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, $ mn 66
Figure 37. Global Biosimilars Market by Indication: Infectious Diseases, 2019-2030, $ mn 67
Figure 38. Global Biosimilars Market by Indication: Other Indications, 2019-2030, $ mn 68
Figure 39. Breakdown of Global Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue 70
Figure 40. Global Addressable Market Cap in 2021-2030 by Manufacturing, Value ($ mn) and Share (%) 70
Figure 41. Global Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, $ mn 71
Figure 42. Global Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, $ mn 72
Figure 43. Breakdown of Global Biosimilars Market by End User, 2019-2030, % of Revenue 74
Figure 44. Global Addressable Market Cap in 2021-2030 by End User, Value ($ mn) and Share (%) 74
Figure 45. Global Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, $ mn 75
Figure 46. Global Biosimilars Market by End User: Research Institutes, 2019-2030, $ mn 76
Figure 47. Global Biosimilars Market by End User: Other End Users, 2019-2030, $ mn 77
Figure 48. Global Market Snapshot by Region 78
Figure 49. Geographic Spread of Worldwide Biosimilars Market, 2019-2030, % of Sales Revenue 79
Figure 50. Global Addressable Market Cap in 2021-2030 by Region, Value ($ mn) and Share (%) 80
Figure 51. North American Biosimilars Market, 2019-2030, $ mn 83
Figure 52. Breakdown of North America Biosimilars Market by Country, 2019 and 2030, % of Revenue 84
Figure 53. Contribution to North America 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%) 85
Figure 54. U.S. Biosimilars Market, 2019-2030, $ mn 87
Figure 55. Biosimilar Approvals and Launches in U.S., 2015-2020 87
Figure 56. Canada Biosimilars Market, 2019-2030, $ mn 96
Figure 57. Biosimilars Market in Mexico, 2019-2030, $ mn 98
Figure 58. European Biosimilars Market, 2019-2030, $ mn 101
Figure 59. Breakdown of European Biosimilars Market by Country, 2019 and 2030, % of Revenue 102
Figure 60. Contribution to Europe 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%) 103
Figure 61. Biosimilars Market in Germany, 2019-2030, $ mn 106
Figure 62. Biosimilars Market in U.K., 2019-2030, $ mn 108
Figure 63. Biosimilars Market in France, 2019-2030, $ mn 110
Figure 64. Biosimilars Market in Spain, 2019-2030, $ mn 112
Figure 65. Biosimilars Market in Italy, 2019-2030, $ mn 114
Figure 66. Biosimilars Market in Russia, 2019-2030, $ mn 116
Figure 67. Biosimilars Market in Rest of Europe, 2019-2030, $ mn 118
Figure 68. Asia-Pacific Biosimilars Market, 2019-2030, $ mn 121
Figure 69. Breakdown of APAC Biosimilars Market by Country, 2019 and 2030, % of Revenue 121
Figure 70. Contribution to APAC 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%) 123
Figure 71. Biosimilars Market in Japan, 2019-2030, $ mn 125
Figure 72. Biosimilars Market in China, 2019-2030, $ mn 127
Figure 73. Biosimilars Market in Australia, 2019-2030, $ mn 129
Figure 74. Biosimilars Market in India, 2019-2030, $ mn 131
Figure 75. Biosimilars Market in South Korea, 2019-2030, $ mn 133
Figure 76. Biosimilars Market in Rest of APAC, 2019-2030, $ mn 135
Figure 77. South America Biosimilars Market, 2019-2030, $ mn 138
Figure 78. Breakdown of South America Biosimilars Market by Country, 2019 and 2030, % of Revenue 138
Figure 79. Contribution to South America 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%) 139
Figure 80. Biosimilars Market in Argentina, 2019-2030, $ mn 140
Figure 81. Biosimilars Market in Brazil, 2019-2030, $ mn 142
Figure 82. Biosimilars Market in Chile, 2019-2030, $ mn 144
Figure 83. Biosimilars Market in Rest of South America, 2019-2030, $ mn 146
Figure 84. Biosimilars Market in Middle East and Africa (MEA), 2019-2030, $ mn 148
Figure 85. Breakdown of MEA Biosimilars Market by Country, 2019 and 2030, % of Revenue 148
Figure 86. Contribution to MEA 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%) 149
Figure 87. Biosimilars Market in Turkey, 2019-2030, $ mn 150
Figure 88. Biosimilars Market in Iran, 2019-2030, $ mn 152
Figure 89. Biosimilars Market in South Africa, 2019-2030, $ mn 154
Figure 90. Growth Stage of Global Biosimilars Industry over the Forecast Period 157

 

Reviews

There are yet no reviews for this product.